Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study-Reference-Cited by-同舟云学术

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

Published:2021-08 Issue:8 Volume:8 Page:e562-e571
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Lynch Ryan C,Cassaday Ryan D,Smith Stephen D,Fromm Jonathan R,Cowan Andrew J,Warren Edus H,Shadman Mazyar S,Shustov Andrei,Till Brian G,Ujjani Chaitra S,Libby Edward N,Philip Mary,Coye Hilary,Martino Christen N,Bhark Sandra L,Morris Karolyn,Rasmussen Heather,Behnia Sanaz,Voutsinas Jenna,Gopal Ajay K

Funder

NCI

Lymphoma Research Foundation of America

Seattle Genetics Inc

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma;Radford;N Engl J Med,2015

2. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial;André;J Clin Oncol,2017

3. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496);Gordon;J Clin Oncol,2013